All In Biotech

Drug Trial Radar · NCT07314567

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

An Open Label, Single Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

22

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Oct 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Relapsed/Refractory Systemic lupus erythematosus (SLE)

Conditions

  • System Lupus Erythematosus(SLE)

Interventions

  • ACE1831Drug

    ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.

  • Lymphodepleting chemotherapyDrug

    Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of ACE1831 in subjects with Refractory Systemic lupus erythematosusTime frame: 24 weeks after last dose of ACE1831

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.